NCT04539041View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy

PHASE1CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

February 16, 2021

Primary Completion Date

October 17, 2024

Study Completion Date

October 17, 2024

Conditions
Progressive Supranuclear Palsy (PSP)
Interventions
DRUG

antisense oligonucleotide

solution of antisense oligonucleotide injected intrathecally (spine tap) at multiple dose levels

DRUG

placebo

placebo for each dose level

Trial Locations (12)

30625

Novartis Investigative Site, Hanover

37221

Vanderbilt University Medical CenterX, Nashville

40225

Novartis Investigative Site, Düsseldorf

53127

Novartis Investigative Site, Bonn

55905

Mayo Clinic Rochester, Rochester

72076

Novartis Investigative Site, Tübingen

81377

Novartis Investigative Site, München

89081

Novartis Investigative Site, Ulm

92037

University of California San Diego, La Jolla

H2X 1R9

Novartis Investigative Site, Montreal

H3A 2B4

Novartis Investigative Site, Montreal

SO16 6YD

Novartis Investigative Site, Southampton

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY